Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors - Research and Markets

Research and Markets
Posted on: 26 Jul 17

The "Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors" report has been added to Research and Markets' offering.

Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?

This report provides an introduction to oncology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications and prognosis. Methods of diagnosis are also provided.

There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.

Key market players (as determined by the total oncology revenue), namely Roche, Celgene, Bristol Myers Squibbs and Novartis, are forecast to maintain their strong market shares throughout the forecast period. Nevertheless, despite the approaching patent expiries of Avastin, Kadcyla, Perjeta and Tarceva, Roche is expected to maintain the highest market share of any company.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Key Marketed Products

4 Pipeline Landscape Assessment

5 Multi-scenario Market Forecast to 2023

6 Company Analysis and Positioning

7 Strategic Consolidations

8 Appendix

Companies Mentioned

- AstraZeneca

- Bristol-Myers Squibb

- Celgene

- Novartis

- Pfizer

- Roche

For more information about this report visit https://www.researchandmarkets.com/research/88r65q/global_oncology

View source version on businesswire.com: http://www.businesswire.com/news/home/20170725006208/en/

Business Wire
www.businesswire.com

Last updated on: 26/07/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.